Reference : Pharmaco-economie des medicaments hypolipidemiants: analyse des facteurs influencant ...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/12907
Pharmaco-economie des medicaments hypolipidemiants: analyse des facteurs influencant le rapport cout/efficacite.
French
[en] Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
1998
Revue Médicale de Liège
CHU de Liège
53
5
270-5
Yes (verified by ORBi)
National
0370-629X
Liège
Belgique
[en] Adult ; Aged ; Anticholesteremic Agents/economics/therapeutic use ; Antilipemic Agents/economics/therapeutic use ; Coronary Disease/prevention & control ; Cost-Benefit Analysis ; Drug Costs ; Economics, Pharmaceutical ; Female ; Heart Diseases/prevention & control ; Humans ; Hypercholesterolemia/drug therapy/prevention & control ; Male ; Middle Aged ; Naphthalenes/economics/therapeutic use ; Risk Factors
[en] The demonstration that stains reduce the risk of cardiovascular diseases, in both secondary and primary prevention trials, led to the recent publication of sophisticated pharmaco-economical studies. A lot of factors may influence the cost-effectiveness ratio of the pharmacological intervention, especially the mode of calculation of various costs, the initial level of cardiovascular risk of the patients and the medico-economical particularities of each country. What so ever, available studies appear to justify the use of statins in secondary prevention, i.e. in coronary patients, even those with only a moderate hypercholesterolaemia, and, in primary prevention, i.e in hypercholesterolaemia individuals with obvious high risk of cardiovascular disease.
http://hdl.handle.net/2268/12907

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.